===========================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
LYNX THERAPEUTICS, INC.
----------------------------
(Name of Issuer)
COMMON STOCK, $.01 PAR VALUE
- ---------------------------------------------------------------------------
(Title of Class of Securities)
551812 30 8
-----------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting
person s initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would later the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be filed for the purpose of Section 18 of the Securities
Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
(Continued on following page(s))
===========================================================================
Page 1 of 10
Exhibit Index is located at page 9
<PAGE> 2
CUSIP No. 551812 30 8
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Citizenship or Place of Organization Delaware
___________________________________________________________________________
5) Sole Voting Power 400,000*
Number of ____________________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 400,000*
Person With ____________________________________________________________
8) Shared Dispositive Power 0
___________________________________________________________________________
9) Aggregate Amount Beneficially Owned 400,000*
by Each Reporting Person
___________________________________________________________________________
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
___________________________________________________________________________
11) Percent of Class Represented 6.36%
by Amount in Row (9)
___________________________________________________________________________
12) Type of Reporting Person CO
___________________________________________________________________________
*Does not include an undetermined number of shares the reporting person is
obligated to purchase upon the happening of a future event.
<PAGE> 3
CUSIP No. 551812 30 8 13G
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Citizenship or Place of Organization Delaware
___________________________________________________________________________
5) Sole Voting Power 400,000*
Number of ____________________________________________________________
Shares
Beneficially 6) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 7) Sole Dispositive Power 400,000*
Person With ____________________________________________________________
8) Shared Dispositive Power 0
___________________________________________________________________________
9) Aggregate Amount Beneficially Owned 400,000*
by Each Reporting Person
___________________________________________________________________________
10) Check Box If the Aggregate Amount [ ]
in Row (9) Excludes Certain Shares
___________________________________________________________________________
11) Percent of Class Represented 6.36%
by Amount in Row (9)
___________________________________________________________________________
12) Type of Reporting Person CO
___________________________________________________________________________
*Does not include an undetermined number of shares the reporting person is
obligated to purchase upon the happening of a future event.
<PAGE> 4
CUSIP No. 551812 30 8 13G
This Statement on Schedule 13G (the "Schedule 13G") with respect to
the Common Stock of Lynx Therapeutics, Inc. (the "Issuer"), is filed
jointly by Hoechst Marion Roussel, Inc., a Delaware corporation ("HMRI"),
and HMR Pharma, Inc., a Delaware corporation ("Pharma"), to (1) replace the
Schedule 13D previously filed by the reporting persons, who have determined
pursuant to SEC Rule 13d-1(h) that the provisions of paragraphs (e), (f),
and (g) of Rule 13d-1 do not apply; and (2) to report the automatic
conversion of the 40,000 shares of Series D Convertible Preferred Stock to
400,000 shares of Common Stock (one-for-ten basis) on March 31, 1998.
ITEM 1(a). NAME OF ISSUER:
- ---------- ---------------
Lynx Therapeutics, Inc.
ITEM 1(b). ADDRESS OF ISSUER S PRINCIPAL EXECUTIVE OFFICES:
- ---------- ------------------------------------------------
3832 Bay Center Place
Hayward, CA 94545
ITEM 2(a). NAME OF PERSON FILING:
- ---------- ----------------------
Hoechst Marion Roussel, Inc.
HMR Pharma, Inc.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
- ---------- ------------------------------------------------------------
Hoechst Marion Roussel, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
ITEM 2(c). CITIZENSHIP:
- ---------- ------------
Delaware As To Both Hoechst Marion Roussel, Inc. And
HMR Pharma, Inc.
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
- ---------- -----------------------------
Common Stock, $.01 Par Value
<PAGE> 5
CUSIP No. 551812 30 8 13G
ITEM 2(e): CUSIP NUMBER:
- ---------- -------------
551812 30 8
ITEM 3: IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(b) OR
13D-2(b):
- ------- -------------------------------------------------------
Not Applicable
ITEM 4. OWNERSHIP
- ------- ---------
(a): AMOUNT BENEFICIALLY OWNED:
400,000 Shares Of Common Stock, effective 03/31/98
upon automatic conversion of 40,000 Shares of Series D
Convertible Preferred Stock on a one-for-ten basis.
(b): PERCENT OF CLASS:
6.36%
(c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:
(i) Sole power to vote or to direct the vote: 400,000*
(ii) Shared power to vote or to direct the vote: 0
(iii) Sole power to dispose or to direct the 400,000*
disposition of:
(iv) Shared power to dispose or to direct the 0
disposition of:
*Does not include an undetermined number of shares the reporting person is
obligated to purchase upon the happening of a future event.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
- ------- ---------------------------------------------
Not Applicable
<PAGE> 6
CUSIP No. 551812 30 8 13G
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
- ------- ----------------------------------------------------------------
Not Applicable
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
- ------- ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY
---------------------------------------------------------------
Not Applicable
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
- ------- ---------------------------------------------------------
Not Applicable
ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
- ------- -------------------------------
Not Applicable
ITEM 10. CERTIFICATION.
- -------- --------------
Not Applicable
<PAGE> 7
CUSIP No. 551812 30 8 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
March 31, 1998
---------------------------------
(Date)
HOECHST MARION ROUSSEL, INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 8
CUSIP No. 551812 30 8 13G
SIGNATURE
----------
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
March 31, 1998
---------------------------------
(Date)
HMR PHARMA, INC.
/s/ Rebecca R. Tilden
---------------------------------
(Signature)
Rebecca R. Tilden
Vice President and Secretary
---------------------------------
(Name/Title)
<PAGE> 9
CUSIP No. 551812 30 8 13G
EXHIBIT INDEX
Exhibit No. Description Page No.
- ----------- ------------ ---------
99.A Agreement to File Jointly dated March 10
31, 1998, by and between Hoechst Marion
Roussel, Inc. and HMR Pharma, Inc.
<PAGE> 10
CUSIP No. 551812 30 8 13G
EXHIBIT 99.A
------------
AGREEMENT TO FILE JOINTLY
We, the undersigned, hereby express our agreement that the attached
Schedule 13G and all subsequent amendments thereto executed by both of us
are filed on behalf of each of us.
HOECHST MARION ROUSSEL, INC.
March 31, 1998 /s/ Rebecca R. Tilden
- --------------------------- -------------------------------------
(Date) (Name and Title)
Rebecca R. Tilden
Vice President and Secretary
HMR PHARMA, INC.
March 31, 1998 /s/ Rebecca R. Tilden
- --------------------------- -------------------------------------
(Date) (Name and Title)
Rebecca R. Tilden
Vice President and Secretary
